Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease

Abstract

Therapeutic strategies with proven efficacy for chronic cutaneous graft-versus-host disease (GvHD) are limited, with long-term oral glucocorticoids remaining the first-line treatment. Prolonged treatment with glucocorticoids contributes to the significantly increased risk of nonrelapse mortality and substantial deficit in quality of life reported in paediatric transplant patients with chronic GvHD. We report a case of atopic dermatitis-like chronic cutaneous GvHD responding to dupilumab, allowing for the eventual withdrawal of oral glucocorticoids.